申请人:Auckland Uniservices Limited
公开号:US07816521B2
公开(公告)日:2010-10-19
The compound 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide and pharmacologically acceptable salts thereof. A method of treating cancer in a subject is also described in which 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof is administered to tumor cells in a hypoxic environment. Also described is a method of radiosensitising in a subject tumor cells of solid tumors in hypoxic conditions by administering to the subject a pharmaceutical composition containing 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof in an amount sufficient to produce radiosensitivity in the tumor cells, and subjecting the tumor cells to radiation. A pharmaceutical composition is additionally provided containing a therapeutically effective amount of 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.
本文描述了化合物3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物及其药学上可接受的盐。还描述了一种治疗受体癌症的方法,其中3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物或其药学上可接受的盐被用于在低氧环境下治疗肿瘤细胞。此外,还提供了一种方法,通过向患者注射含有3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物或其药学上可接受的盐的药物组合物,以在低氧条件下使实体瘤中的肿瘤细胞放射敏感性,然后将肿瘤细胞暴露于放射线。此外,还提供了一种药物组合物,其中包含治疗有效量的3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物或其药学上可接受的盐和药学上可接受的赋形剂、辅料、载体、缓冲剂或稳定剂。